The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Engineered Subunit Vaccine Market Research Report 2025
Synopsis
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
The global Gene Engineered Subunit Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gene Engineered Subunit Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Engineered Subunit Vaccine.
Report Scope
The Gene Engineered Subunit Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Engineered Subunit Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Engineered Subunit Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
Novavax
Sanofi Pasteur
Bharat Biotech
GlaxoSmithKline
Pfizer
Moderna
Segment by Type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Segment by Application
Human Use
Veterinary Use
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gene Engineered Subunit Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gene Engineered Subunit Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
The global Gene Engineered Subunit Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gene Engineered Subunit Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Engineered Subunit Vaccine.
Report Scope
The Gene Engineered Subunit Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Engineered Subunit Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Engineered Subunit Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
Novavax
Sanofi Pasteur
Bharat Biotech
GlaxoSmithKline
Pfizer
Moderna
Segment by Type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Segment by Application
Human Use
Veterinary Use
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gene Engineered Subunit Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gene Engineered Subunit Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Gene Engineered Subunit Vaccine Market Overview
1.1 Product Overview and Scope of Gene Engineered Subunit Vaccine
1.2 Gene Engineered Subunit Vaccine Segment by Type
1.2.1 Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Therapeutic Gene Engineered Subunit Vaccine
1.2.3 Preventative Gene Engineered Subunit Vaccine
1.3 Gene Engineered Subunit Vaccine Segment by Application
1.3.1 Global Gene Engineered Subunit Vaccine Market Value by Application: (2024-2030)
1.3.2 Human Use
1.3.3 Veterinary Use
1.4 Global Gene Engineered Subunit Vaccine Market Size Estimates and Forecasts
1.4.1 Global Gene Engineered Subunit Vaccine Revenue 2019-2030
1.4.2 Global Gene Engineered Subunit Vaccine Sales 2019-2030
1.4.3 Global Gene Engineered Subunit Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Gene Engineered Subunit Vaccine Market Competition by Manufacturers
2.1 Global Gene Engineered Subunit Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Gene Engineered Subunit Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Gene Engineered Subunit Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gene Engineered Subunit Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gene Engineered Subunit Vaccine, Product Type & Application
2.7 Gene Engineered Subunit Vaccine Market Competitive Situation and Trends
2.7.1 Gene Engineered Subunit Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gene Engineered Subunit Vaccine Players Market Share by Revenue
2.7.3 Global Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gene Engineered Subunit Vaccine Retrospective Market Scenario by Region
3.1 Global Gene Engineered Subunit Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Gene Engineered Subunit Vaccine Global Gene Engineered Subunit Vaccine Sales by Region: 2019-2030
3.2.1 Global Gene Engineered Subunit Vaccine Sales by Region: 2019-2024
3.2.2 Global Gene Engineered Subunit Vaccine Sales by Region: 2025-2030
3.3 Global Gene Engineered Subunit Vaccine Global Gene Engineered Subunit Vaccine Revenue by Region: 2019-2030
3.3.1 Global Gene Engineered Subunit Vaccine Revenue by Region: 2019-2024
3.3.2 Global Gene Engineered Subunit Vaccine Revenue by Region: 2025-2030
3.4 North America Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.4.1 North America Gene Engineered Subunit Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Gene Engineered Subunit Vaccine Sales by Country (2019-2030)
3.4.3 North America Gene Engineered Subunit Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.5.1 Europe Gene Engineered Subunit Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2030)
3.5.3 Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Gene Engineered Subunit Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Gene Engineered Subunit Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Gene Engineered Subunit Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.7.1 Latin America Gene Engineered Subunit Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Gene Engineered Subunit Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Gene Engineered Subunit Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Gene Engineered Subunit Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gene Engineered Subunit Vaccine Sales by Type (2019-2030)
4.1.1 Global Gene Engineered Subunit Vaccine Sales by Type (2019-2024)
4.1.2 Global Gene Engineered Subunit Vaccine Sales by Type (2025-2030)
4.1.3 Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Gene Engineered Subunit Vaccine Revenue by Type (2019-2030)
4.2.1 Global Gene Engineered Subunit Vaccine Revenue by Type (2019-2024)
4.2.2 Global Gene Engineered Subunit Vaccine Revenue by Type (2025-2030)
4.2.3 Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Gene Engineered Subunit Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Gene Engineered Subunit Vaccine Sales by Application (2019-2030)
5.1.1 Global Gene Engineered Subunit Vaccine Sales by Application (2019-2024)
5.1.2 Global Gene Engineered Subunit Vaccine Sales by Application (2025-2030)
5.1.3 Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Gene Engineered Subunit Vaccine Revenue by Application (2019-2030)
5.2.1 Global Gene Engineered Subunit Vaccine Revenue by Application (2019-2024)
5.2.2 Global Gene Engineered Subunit Vaccine Revenue by Application (2025-2030)
5.2.3 Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Gene Engineered Subunit Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Gene Engineered Subunit Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Gene Engineered Subunit Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Tiantan
6.3.1 Tiantan Corporation Information
6.3.2 Tiantan Description and Business Overview
6.3.3 Tiantan Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Tiantan Gene Engineered Subunit Vaccine Product Portfolio
6.3.5 Tiantan Recent Developments/Updates
6.4 Pulike
6.4.1 Pulike Corporation Information
6.4.2 Pulike Description and Business Overview
6.4.3 Pulike Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pulike Gene Engineered Subunit Vaccine Product Portfolio
6.4.5 Pulike Recent Developments/Updates
6.5 Greffex
6.5.1 Greffex Corporation Information
6.5.2 Greffex Description and Business Overview
6.5.3 Greffex Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Greffex Gene Engineered Subunit Vaccine Product Portfolio
6.5.5 Greffex Recent Developments/Updates
6.6 CureVac
6.6.1 CureVac Corporation Information
6.6.2 CureVac Description and Business Overview
6.6.3 CureVac Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CureVac Gene Engineered Subunit Vaccine Product Portfolio
6.6.5 CureVac Recent Developments/Updates
6.7 Yebio
6.6.1 Yebio Corporation Information
6.6.2 Yebio Description and Business Overview
6.6.3 Yebio Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Yebio Gene Engineered Subunit Vaccine Product Portfolio
6.7.5 Yebio Recent Developments/Updates
6.8 Sanofi Pasteur SA
6.8.1 Sanofi Pasteur SA Corporation Information
6.8.2 Sanofi Pasteur SA Description and Business Overview
6.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolio
6.8.5 Sanofi Pasteur SA Recent Developments/Updates
6.9 Virbac
6.9.1 Virbac Corporation Information
6.9.2 Virbac Description and Business Overview
6.9.3 Virbac Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Virbac Gene Engineered Subunit Vaccine Product Portfolio
6.9.5 Virbac Recent Developments/Updates
6.10 Pfizer Inc.
6.10.1 Pfizer Inc. Corporation Information
6.10.2 Pfizer Inc. Description and Business Overview
6.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolio
6.10.5 Pfizer Inc. Recent Developments/Updates
6.11 Walvax Biotechnology
6.11.1 Walvax Biotechnology Corporation Information
6.11.2 Walvax Biotechnology Gene Engineered Subunit Vaccine Description and Business Overview
6.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolio
6.11.5 Walvax Biotechnology Recent Developments/Updates
6.12 Kontec
6.12.1 Kontec Corporation Information
6.12.2 Kontec Gene Engineered Subunit Vaccine Description and Business Overview
6.12.3 Kontec Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Kontec Gene Engineered Subunit Vaccine Product Portfolio
6.12.5 Kontec Recent Developments/Updates
6.13 Novavax
6.13.1 Novavax Corporation Information
6.13.2 Novavax Gene Engineered Subunit Vaccine Description and Business Overview
6.13.3 Novavax Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Novavax Gene Engineered Subunit Vaccine Product Portfolio
6.13.5 Novavax Recent Developments/Updates
6.14 Sanofi Pasteur
6.14.1 Sanofi Pasteur Corporation Information
6.14.2 Sanofi Pasteur Gene Engineered Subunit Vaccine Description and Business Overview
6.14.3 Sanofi Pasteur Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolio
6.14.5 Sanofi Pasteur Recent Developments/Updates
6.15 Bharat Biotech
6.15.1 Bharat Biotech Corporation Information
6.15.2 Bharat Biotech Gene Engineered Subunit Vaccine Description and Business Overview
6.15.3 Bharat Biotech Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolio
6.15.5 Bharat Biotech Recent Developments/Updates
6.16 GlaxoSmithKline
6.16.1 GlaxoSmithKline Corporation Information
6.16.2 GlaxoSmithKline Gene Engineered Subunit Vaccine Description and Business Overview
6.16.3 GlaxoSmithKline Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolio
6.16.5 GlaxoSmithKline Recent Developments/Updates
6.17 Pfizer
6.17.1 Pfizer Corporation Information
6.17.2 Pfizer Gene Engineered Subunit Vaccine Description and Business Overview
6.17.3 Pfizer Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Pfizer Gene Engineered Subunit Vaccine Product Portfolio
6.17.5 Pfizer Recent Developments/Updates
6.18 Moderna
6.18.1 Moderna Corporation Information
6.18.2 Moderna Gene Engineered Subunit Vaccine Description and Business Overview
6.18.3 Moderna Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Moderna Gene Engineered Subunit Vaccine Product Portfolio
6.18.5 Moderna Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gene Engineered Subunit Vaccine Industry Chain Analysis
7.2 Gene Engineered Subunit Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gene Engineered Subunit Vaccine Production Mode & Process
7.4 Gene Engineered Subunit Vaccine Sales and Marketing
7.4.1 Gene Engineered Subunit Vaccine Sales Channels
7.4.2 Gene Engineered Subunit Vaccine Distributors
7.5 Gene Engineered Subunit Vaccine Customers
8 Gene Engineered Subunit Vaccine Market Dynamics
8.1 Gene Engineered Subunit Vaccine Industry Trends
8.2 Gene Engineered Subunit Vaccine Market Drivers
8.3 Gene Engineered Subunit Vaccine Market Challenges
8.4 Gene Engineered Subunit Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Gene Engineered Subunit Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Gene Engineered Subunit Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Gene Engineered Subunit Vaccine Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global Gene Engineered Subunit Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Gene Engineered Subunit Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Gene Engineered Subunit Vaccine Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Gene Engineered Subunit Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gene Engineered Subunit Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Engineered Subunit Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gene Engineered Subunit Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Gene Engineered Subunit Vaccine Sales by Region (2019-2024) & (K Dose)
Table 18. Global Gene Engineered Subunit Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Gene Engineered Subunit Vaccine Sales by Region (2025-2030) & (K Dose)
Table 20. Global Gene Engineered Subunit Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Gene Engineered Subunit Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Gene Engineered Subunit Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Gene Engineered Subunit Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Gene Engineered Subunit Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Gene Engineered Subunit Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 27. North America Gene Engineered Subunit Vaccine Sales by Country (2025-2030) & (K Dose)
Table 28. North America Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Gene Engineered Subunit Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Gene Engineered Subunit Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 32. Europe Gene Engineered Subunit Vaccine Sales by Country (2025-2030) & (K Dose)
Table 33. Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Gene Engineered Subunit Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Gene Engineered Subunit Vaccine Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific Gene Engineered Subunit Vaccine Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gene Engineered Subunit Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America Gene Engineered Subunit Vaccine Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Gene Engineered Subunit Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Type (2019-2024)
Table 51. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Type (2025-2030)
Table 52. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2019-2024)
Table 59. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2025-2030)
Table 60. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Application (2019-2024)
Table 61. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Application (2025-2030)
Table 62. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2019-2024)
Table 69. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. Merck Gene Engineered Subunit Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. GSK Gene Engineered Subunit Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Tiantan Corporation Information
Table 81. Tiantan Description and Business Overview
Table 82. Tiantan Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Tiantan Gene Engineered Subunit Vaccine Product
Table 84. Tiantan Recent Developments/Updates
Table 85. Pulike Corporation Information
Table 86. Pulike Description and Business Overview
Table 87. Pulike Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. Pulike Gene Engineered Subunit Vaccine Product
Table 89. Pulike Recent Developments/Updates
Table 90. Greffex Corporation Information
Table 91. Greffex Description and Business Overview
Table 92. Greffex Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Greffex Gene Engineered Subunit Vaccine Product
Table 94. Greffex Recent Developments/Updates
Table 95. CureVac Corporation Information
Table 96. CureVac Description and Business Overview
Table 97. CureVac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. CureVac Gene Engineered Subunit Vaccine Product
Table 99. CureVac Recent Developments/Updates
Table 100. Yebio Corporation Information
Table 101. Yebio Description and Business Overview
Table 102. Yebio Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Yebio Gene Engineered Subunit Vaccine Product
Table 104. Yebio Recent Developments/Updates
Table 105. Sanofi Pasteur SA Corporation Information
Table 106. Sanofi Pasteur SA Description and Business Overview
Table 107. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product
Table 109. Sanofi Pasteur SA Recent Developments/Updates
Table 110. Virbac Corporation Information
Table 111. Virbac Description and Business Overview
Table 112. Virbac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. Virbac Gene Engineered Subunit Vaccine Product
Table 114. Virbac Recent Developments/Updates
Table 115. Pfizer Inc. Corporation Information
Table 116. Pfizer Inc. Description and Business Overview
Table 117. Pfizer Inc. Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 118. Pfizer Inc. Gene Engineered Subunit Vaccine Product
Table 119. Pfizer Inc. Recent Developments/Updates
Table 120. Walvax Biotechnology Corporation Information
Table 121. Walvax Biotechnology Description and Business Overview
Table 122. Walvax Biotechnology Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 123. Walvax Biotechnology Gene Engineered Subunit Vaccine Product
Table 124. Walvax Biotechnology Recent Developments/Updates
Table 125. Kontec Corporation Information
Table 126. Kontec Description and Business Overview
Table 127. Kontec Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 128. Kontec Gene Engineered Subunit Vaccine Product
Table 129. Kontec Recent Developments/Updates
Table 130. Novavax Corporation Information
Table 131. Novavax Description and Business Overview
Table 132. Novavax Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 133. Novavax Gene Engineered Subunit Vaccine Product
Table 134. Novavax Recent Developments/Updates
Table 135. Sanofi Pasteur Corporation Information
Table 136. Sanofi Pasteur Description and Business Overview
Table 137. Sanofi Pasteur Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 138. Sanofi Pasteur Gene Engineered Subunit Vaccine Product
Table 139. Sanofi Pasteur Recent Developments/Updates
Table 140. Bharat Biotech Corporation Information
Table 141. Bharat Biotech Description and Business Overview
Table 142. Bharat Biotech Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 143. Bharat Biotech Gene Engineered Subunit Vaccine Product
Table 144. Bharat Biotech Recent Developments/Updates
Table 145. GlaxoSmithKline Corporation Information
Table 146. GlaxoSmithKline Description and Business Overview
Table 147. GlaxoSmithKline Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 148. GlaxoSmithKline Gene Engineered Subunit Vaccine Product
Table 149. GlaxoSmithKline Recent Developments/Updates
Table 150. Pfizer Corporation Information
Table 151. Pfizer Description and Business Overview
Table 152. Pfizer Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 153. Pfizer Gene Engineered Subunit Vaccine Product
Table 154. Pfizer Recent Developments/Updates
Table 155. Moderna Corporation Information
Table 156. Moderna Description and Business Overview
Table 157. Moderna Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 158. Moderna Gene Engineered Subunit Vaccine Product
Table 159. Moderna Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Gene Engineered Subunit Vaccine Distributors List
Table 163. Gene Engineered Subunit Vaccine Customers List
Table 164. Gene Engineered Subunit Vaccine Market Trends
Table 165. Gene Engineered Subunit Vaccine Market Drivers
Table 166. Gene Engineered Subunit Vaccine Market Challenges
Table 167. Gene Engineered Subunit Vaccine Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Gene Engineered Subunit Vaccine
Figure 2. Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Gene Engineered Subunit Vaccine Market Share by Type in 2023 & 2030
Figure 4. Therapeutic Gene Engineered Subunit Vaccine Product Picture
Figure 5. Preventative Gene Engineered Subunit Vaccine Product Picture
Figure 6. Global Gene Engineered Subunit Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Gene Engineered Subunit Vaccine Market Share by Application in 2023 & 2030
Figure 8. Human Use
Figure 9. Veterinary Use
Figure 10. Global Gene Engineered Subunit Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Gene Engineered Subunit Vaccine Market Size (2019-2030) & (US$ Million)
Figure 12. Global Gene Engineered Subunit Vaccine Sales (2019-2030) & (K Dose)
Figure 13. Global Gene Engineered Subunit Vaccine Average Price (US$/Dose) & (2019-2030)
Figure 14. Gene Engineered Subunit Vaccine Report Years Considered
Figure 15. Gene Engineered Subunit Vaccine Sales Share by Manufacturers in 2023
Figure 16. Global Gene Engineered Subunit Vaccine Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Gene Engineered Subunit Vaccine Players: Market Share by Revenue in 2023
Figure 18. Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Gene Engineered Subunit Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2030)
Figure 21. North America Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2030)
Figure 25. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2030)
Figure 26. Germany Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Gene Engineered Subunit Vaccine Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Gene Engineered Subunit Vaccine Revenue Market Share by Region (2019-2030)
Figure 33. China Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2030)
Figure 44. Latin America Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Gene Engineered Subunit Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Gene Engineered Subunit Vaccine by Type (2019-2030)
Figure 54. Global Revenue Market Share of Gene Engineered Subunit Vaccine by Type (2019-2030)
Figure 55. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2019-2030)
Figure 56. Global Sales Market Share of Gene Engineered Subunit Vaccine by Application (2019-2030)
Figure 57. Global Revenue Market Share of Gene Engineered Subunit Vaccine by Application (2019-2030)
Figure 58. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2019-2030)
Figure 59. Gene Engineered Subunit Vaccine Value Chain
Figure 60. Gene Engineered Subunit Vaccine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
